Skip to main content

Advertisement

SpringerLink
Log in

Abuse-deterrent opioid formulations: Are they a pipe dream?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The continued need for opioids to treat pain and their unavoidable link to abuse and addiction create a need for risk mitigation approaches that optimize their risk-benefit ratio. Abuse-deterrent formulations (ADFs) have emerged as a means for supporting opioid access while limiting abuse and its consequences. Several different types of ADFs have emerged including physical barriers to tampering, agonist-antagonist formulations, aversion, prodrugs, and alternative methods of administration. Each of these types has the potential to reduce specific forms of prescription opioid abuse. ADFs have the potential to reduce the public health burden of prescription opioid abuse, but they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Katz NP, Adams EH, Benneyan JC, et al.: Foundations of opioid risk management. Clin J Pain 2007, 23:103–118.

    Article  PubMed  Google Scholar 

  2. Savage S, Covington EC, Heit HA, et al.: Definitions related to the use of opioids for the treatment of pain. American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine, 2007. Available at http://www.ampainsoc.org/advocacy/opioids2.htm. Accessed November 28, 2007.

  3. Katz NP, Adams EH, Chilcoat H, et al.: Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007, 23:648–660.

    Article  PubMed  Google Scholar 

  4. Substance Abuse and Mental Health Services Administration: Results from the 2006 National Survey on Drug Use and Health: National Findings. (Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. SMA 07-4293). Rockville, MD: Department of Health and Human Services; 2007.

  5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4 edn, text revision.

  6. O’Brien CP, Volkow N, Li TK: What’s in a word? Addiction vs. dependence in DSM-V. Am J Psychiatry 2006, 163:764–765.

    Article  PubMed  Google Scholar 

  7. Hays LR: A profile of OxyContin addiction. J Addict Dis 2004, 23:1–9.

    Article  PubMed  Google Scholar 

  8. White AG, Birnbaum HG, Mareva MN, et al.: Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005, 11:469–479.

    PubMed  Google Scholar 

  9. Compton WM, Volkow ND: Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006, 83(Suppl 1):S4–S7.

    Article  PubMed  CAS  Google Scholar 

  10. Marsch LA, Bickel WK, Badger GJ, et al.: Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001, 299:1056–1065.

    PubMed  CAS  Google Scholar 

  11. Rosenblum A, Parrino M, Schnoll SH, et al.: Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007, 90:64–71.

    Article  PubMed  Google Scholar 

  12. Butler S, Budman S, Villapiano A, et al.: The NAVIPPRO System: new data on the feasibility of real-time, product specific opioid surveillance. Presented at the American Pain Society Annual Meeting. Washington, DC; May 2–7, 2007.

  13. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE: Monitoring the future national results on adolescent drug use: overview of key findings, 2006. (NIH Publication No. 07-6202). Bethesda, MD: National Institute on Drug Abuse; 2007.

    Google Scholar 

  14. Watson WA, Litovitz TL, Rodgers GC Jr, et al.: 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005, 23:589–666.

    Article  PubMed  Google Scholar 

  15. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2005: National estimates of drug-related emergency department visits. (DAWN Series D-29, DHHS Publication No. SMA 07-4256.) Rockville, MD: Department of Health and Human Services; 2007.

  16. Passik SD, Kirsh KL, Donaghy KB, Portenoy RK: Pain and aberrant drug-related behaviors in medically ill patients with and without histories of substance abuse. Clin J Pain 2006, 22:173–181.

    Article  PubMed  Google Scholar 

  17. Paulozzi LJ, Ryan GW: Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 2006, 31:506–511.

    Article  PubMed  Google Scholar 

  18. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Drug Abuse Warning Network, 2003: area profiles of drug-related mortality. (DAWN Series D-27, DHHS Publication No. SMA 05-4023.) Rockville, MD: Department of Health and Human Services; 2005.

  19. Substance Abuse and Mental Health Services Administration, Office of Applied Studies: Disposition of emergency department visits for drug-related suicide attempts by adolescents: 2004. The New DAWN Report. Issue 6. Rockville, MD: Department of Health and Human Services; 2006.

  20. Booth M: Opium: A History. New York: St. Martins Press; 1996.

    Google Scholar 

  21. Fudala PJ, Johnson RE: Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006, 83(Suppl 1):S40–S47.

    Article  PubMed  CAS  Google Scholar 

  22. Katz NP, Buse DC, Budman SH, et al.: Development and preliminary experience with an ease of extractability rating system for prescription opioids. Drug Dev Ind Pharm 2006, 32:727–746.

    Article  PubMed  CAS  Google Scholar 

  23. Cone EJ: Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet. Drug Alcohol Depend 2006, 83(Suppl 1):S31–S39.

    Article  PubMed  Google Scholar 

  24. Webster LR: PTI-821: sustained-release oxycodone using gel-cap technology. Expert Opin Investig Drugs 2007, 16:359–366.

    Article  PubMed  CAS  Google Scholar 

  25. Bartholomaeus J, Arkenau E, Ashworth JB: A new technology to increase the mechanical stability of matrix tablets to prevent abuse by crushing or chewing. Presented at the College of Problems in Drug Dependency. Bethesda, MD; April 19–20, 2005.

  26. Collegium Pharmaceutical: Central nervous system. Available at http://www.collegiumpharma.com/products/cns.html. Accessed November 28, 2007.

  27. Parasrampuria DA, Schoedel KA, Schuller R, et al.: Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007, 27:459–467.

    Article  PubMed  CAS  Google Scholar 

  28. Teter CJ, McCabe SE, LaGrange K, et al.: Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006, 26:1501–1510.

    Article  PubMed  Google Scholar 

  29. Lahmeyer HW, Craig RJ: Pentazocine-naloxone: another “addiction-proof” drug of abuse. Int J Addict 1987, 22:1163–1166.

    PubMed  CAS  Google Scholar 

  30. Alho H, Sinclair D, Vuori E, Holopainen A: Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007, 88:75–78.

    Article  PubMed  CAS  Google Scholar 

  31. US Food and Drug Administration, Center for Drug Evaluation and Research: Subutex and Suboxone: questions and answers. Available at http://www.fda.gov/cder/drug/infopage/subutex_suboxone/subutex-qa.htm. Accessed November 28, 2007.

  32. Katz N, Sun S, Fox L, et al.: Treatment of osteoarthritis pain with extended-release morphine sulfate plus sequestered naltrexone ASA 2007 Annual Meeting [abstract #652984]. Presented at the American Society of Anesthesiologists. San Francisco, CA; October 15, 2007.

  33. Elite Pharmaceuticals Inc.: Home page. Available at www.elitepharma.com. Accessed November 28, 2007.

  34. Woolf CJ, Hashmi M: Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Investig Drugs 2004, 5:61–66.

    PubMed  Google Scholar 

  35. Gershell L, Goater JJ: From the analyst’s couch: making gains in pain. Nat Rev Drug Discov 2006, 5:889–890.

    Article  PubMed  CAS  Google Scholar 

  36. Acura Pharmaceuticals Inc.: Home page. Available at http://www.acurapharm.com. Accessed November 28, 2007.

  37. Vyvanse [package insert]. Hampshire, UK: Shire Pharmaceuticals; 2007.

  38. Rosenblum A, Parrino M, Schnoll SH, et al.: Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007, 90:64–71.

    Article  PubMed  Google Scholar 

  39. Butler SF, Benoit CM, Budman SH, et al.: Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J 2006, 3:5.

    Article  PubMed  Google Scholar 

  40. Bell J, White J, Saunders J, et al.: PROBUPHINE (buprenorphine implant) provides sustained serum buprenorphine concentrations and long-term control of withdrawal symptoms and cravings [poster]. Presented at the College on Problems of Drug Dependence 66th Annual Scientific Meeting. San Juan, Puerto Rico; June 12–17, 2004.

  41. Sobel BF, Sigmon SC, Walsh SL, et al.: Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 2004, 73:11–22.

    Article  PubMed  CAS  Google Scholar 

  42. Katz N, Fanciullo GJ: Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002, 18(4 Suppl):S76–S82.

    Article  PubMed  Google Scholar 

  43. Ives TJ, Chelminski PR, Hammett-Stabler CA, et al.: Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006, 6:46.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Analgesic Research, 109 Highland Avenue, Suite B2, Needham, MA, 02494, USA

    Nathaniel Katz

Authors
  1. Nathaniel Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathaniel Katz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katz, N. Abuse-deterrent opioid formulations: Are they a pipe dream?. Curr Rheumatol Rep 10, 11–18 (2008). https://doi.org/10.1007/s11926-008-0003-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0003-z

Keywords

Search

Navigation